Skip to main content
. 2022 Sep 28;50:40–49. doi: 10.1016/j.athplu.2022.09.001

Fig. 1.

Fig. 1

TACE/ADAM17 substrates in ACS and follow-up MACE. Levels of TACE/ADAM17 substrates TRANCE, LDLR, LAG-3 and ACE2 were significantly higher in CAD patients compared to controls. Levels of HB-EGF, Ep-CAM, TNFR1 were able to accurately classify ACS patients and levels of TNFR1 and TNFR2 associated with MACE upon follow-up. TACE inhibitor, TIMP3 mRNA levels were lower in CAD patients and tended to be lower in ACS compared to elective CAD patients.